NASDAQ:OMCLOmnicell Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Omnicell, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $64.83 +0.06 (+0.09 %) (As of 07/10/2020 04:00 PM ET) Add Compare Share Today's Range$64.60Now: $64.83▼$65.8450-Day Range$64.00MA: $67.47▼$72.3352-Week Range$54.24Now: $64.83▼$94.85Volume138,000 shsAverage Volume314,424 shsMarket Capitalization$2.76 billionP/E Ratio40.52Dividend YieldN/ABeta1.03 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Omnicell, Inc. provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides automated dispensing cabinets for medications and supplies used in nursing units, operating rooms, and emergency departments; analytics software to monitor drug diversion and address inventory management issues; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems used in hospitals and retail pharmacies for handling the stocking and retrieval of boxed medications. The Medication Adherence segment provides medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings; automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; and semi-automated filling equipment for the long-term care institutional pharmacy. It also offers Omnicell Patient Engagement, a subscription-based software system; patient communication tools, such as interactive voice response for pharmacies; and electronic Medication Administration Record software for use in nursing homes. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingOmnicell has received a consensus rating of Buy. The company's average rating score is 2.63, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $85.63, Omnicell has a potential upside of 32.1% from its current price of $64.83.Amount of Analyst CoverageOmnicell has only been the subject of 4 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesOmnicell has received 454 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOmnicell has received 355 “underperform” votes. (Add your “underperform” vote.)Community SentimentOmnicell has received 56.12% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Omnicell and other stocks. Vote “Outperform” if you believe OMCL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OMCL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOmnicell does not currently pay a dividend.Dividend GrowthOmnicell does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Omnicell insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $143,862.00 in company stock.Percentage Held by InsidersOnly 2.63% of the stock of Omnicell is held by insiders.Percentage Held by Institutions95.89% of the stock of Omnicell is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Omnicell are expected to grow by 28.99% in the coming year, from $1.69 to $2.18 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Omnicell is 40.52, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.04.Price to Earnings Ratio vs. SectorThe P/E ratio of Omnicell is 40.52, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.56.Price to Earnings Growth RatioOmnicell has a PEG Ratio of 2.55. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioOmnicell has a P/B Ratio of 3.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.67 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Electronic computers Sub-IndustryHealth Care Technology SectorMedical Current SymbolNASDAQ:OMCL Previous Symbol CUSIP68213N10 CIK926326 Webwww.omnicell.com Phone650-251-6100Debt Debt-to-Equity RatioN/A Current Ratio1.93 Quick Ratio1.47Price-To-Earnings Trailing P/E Ratio40.52 Forward P/E Ratio38.36 P/E Growth2.55 Sales & Book Value Annual Sales$897.03 million Price / Sales3.08 Cash Flow$3.82 per share Price / Cash Flow16.96 Book Value$20.16 per share Price / Book3.22Profitability EPS (Most Recent Fiscal Year)$2.19 Net Income$61.34 million Net Margins7.51% Return on Equity11.37% Return on Assets7.65%Miscellaneous Employees2,700 Outstanding Shares42,620,000Market Cap$2.76 billion Next Earnings Date7/23/2020 (Estimated) OptionableOptionable NASDAQ:OMCL Rates by TradingView Receive OMCL News and Ratings via Email Sign-up to receive the latest news and ratings for OMCL and its competitors with MarketBeat's FREE daily newsletter. Omnicell (NASDAQ:OMCL) Frequently Asked Questions How has Omnicell's stock been impacted by COVID-19 (Coronavirus)? Omnicell's stock was trading at $77.41 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, OMCL shares have decreased by 16.3% and is now trading at $64.83. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Omnicell? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Omnicell. When is Omnicell's next earnings date? Omnicell is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for Omnicell. How were Omnicell's earnings last quarter? Omnicell, Inc. (NASDAQ:OMCL) announced its quarterly earnings data on Thursday, May, 7th. The company reported $0.66 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.51 by $0.15. The firm had revenue of $229.69 million for the quarter, compared to analysts' expectations of $218.99 million. Omnicell had a net margin of 7.51% and a return on equity of 11.37%. Omnicell's revenue for the quarter was up 13.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.61 EPS. View Omnicell's earnings history. What price target have analysts set for OMCL? 8 brokerages have issued 12-month target prices for Omnicell's stock. Their forecasts range from $76.00 to $100.00. On average, they expect Omnicell's stock price to reach $85.63 in the next year. This suggests a possible upside of 32.1% from the stock's current price. View analysts' price targets for Omnicell. Has Omnicell been receiving favorable news coverage? News articles about OMCL stock have been trending somewhat negative this week, InfoTrie reports. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Omnicell earned a coverage optimism score of -1.2 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about Omnicell. Who are some of Omnicell's key competitors? Some companies that are related to Omnicell include Cerner (CERN), HMS (HMSY), Cortexyme (CRTX), Allscripts Healthcare Solutions (MDRX), HealthStream (HSTM), Vocera Communications (VCRA) and Computer Programs & Systems (CPSI). View all competitors. What other stocks do shareholders of Omnicell own? Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), AbbVie (ABBV), Johnson & Johnson (JNJ), Adobe (ADBE), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), NVIDIA (NVDA) and Applied Materials (AMAT). Who are Omnicell's key executives? Omnicell's management team includes the following people: Mr. Randall A. Lipps, Founder, Exec. Chairman, Pres & CEO (Age 62)Mr. Peter J. Kuipers, Exec. VP & CFO (Age 47)Mr. Daniel S. Johnston, Exec. VP, Chief Legal & Admin. Officer and Corp. Sec. (Age 55)Mr. Joseph Brian Spears, VP of Corp. Fin. & Chief Accounting Officer (Age 59)Mr. Nhat H. Ngo, Exec. VP of Marketing, Strategy & Bus. Devel. (Age 46) What is Omnicell's stock symbol? Omnicell trades on the NASDAQ under the ticker symbol "OMCL." Who are Omnicell's major shareholders? Omnicell's stock is owned by a variety of retail and institutional investors. Top institutional investors include Envestnet Asset Management Inc. (0.16%), State of Alaska Department of Revenue (0.09%), Watchman Group Inc. (0.05%), DNB Asset Management AS (0.05%) and Diversified Trust Co (0.01%). Company insiders that own Omnicell stock include Dan S Johnston, Gary S Petersmeyer, James T Judson, Joanne B Bauer, Jorge R Taborga, Joseph Brian Spears, Nhat H Ngo, Peter J Kuipers, Randall A Lipps and Scott Peter Seidelmann. View institutional ownership trends for Omnicell. Which major investors are buying Omnicell stock? OMCL stock was purchased by a variety of institutional investors in the last quarter, including Watchman Group Inc., Envestnet Asset Management Inc., Diversified Trust Co, DNB Asset Management AS, and State of Alaska Department of Revenue. View insider buying and selling activity for Omnicell. How do I buy shares of Omnicell? Shares of OMCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Omnicell's stock price today? One share of OMCL stock can currently be purchased for approximately $64.83. How big of a company is Omnicell? Omnicell has a market capitalization of $2.76 billion and generates $897.03 million in revenue each year. The company earns $61.34 million in net income (profit) each year or $2.19 on an earnings per share basis. Omnicell employs 2,700 workers across the globe. What is Omnicell's official website? The official website for Omnicell is www.omnicell.com. How can I contact Omnicell? Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-251-6100 or via email at [email protected] This page was last updated on 7/11/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
